Use of FLT3 ligand for enhancing immune responses in RNA immunization
US-9486519-B2 · Nov 8, 2016 · US
Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
US11246908B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11246908-B2 |
| Application number | US-201916244200-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 10, 2019 |
| Priority date | Jan 10, 2018 |
| Publication date | Feb 15, 2022 |
| Grant date | Feb 15, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a polypeptide that comprises a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1. 2. The composition of claim 1 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1. 3. The composition of claim 1 , further comprising at least one chemotherapeutic agent. 4. The composition of claim 1 , further comprising at least one immunotherapeutic agent. 5. The composition of claim 1 wherein the polypeptide is therapeutically effective. 6. A composition comprising a polypeptide that comprises a sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 1. 7. A composition comprising a fusion polypeptide comprising albumin protein linked to a FMS-like tyrosine kinase 3 ligand (Flt3L) protein, and wherein the albumin protein is murine. 8. The composition of claim 7 wherein the Flt3L protein is murine. 9. The composition of claim 7 having the amino acid sequence of SEQ ID NO: 2. 10. The composition of claim 7 having the amino acid sequence of SEQ ID NO: 3. 11. The composition of claim 7 , further comprising a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Cytokines; Lymphokines; Interferons · CPC title
- A61K38/1793Primary
for cytokines; for lymphokines; for interferons · CPC title
Cytokines; Lymphokines; Interferons · CPC title
Antineoplastic agents · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11246908B2 cover?
- The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1793. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).